[Skip to content]

European Parkinson's Disease Association
Search our Site
.

Research papers

Search

Mechanisms research papers

  • Movement Disorders Volume 31 Issue 1 GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's diseaseConclusions: Both GBA mutations and E326K are associated with a distinct cognitive profile characterized by greater impairment in working memory/executive function and visuospatial abilities in PD patients. The discovery that E326K negatively impacts cognitive performance approximately doubles the proportion of PD patients we now recognize are at risk for more severe GBA-related cognitive deficits. 15 January 2016
  • Brain Research Vol 1625 BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinsons diseaseDouble-lesioned rats treated with rasagiline or aminoindan exhibited a sparing in the mitochondrial marker Hsp60 immunoreactivity, suggesting mitochondrial involvement in neuroprotection. Tyrosine hydroxylase (TH) immunohistochemistry revealed a sparing of TH-immunoreactive terminals in double-lesioned rats treated with rasagiline or aminoindan in the striatum, hippocampus, and substantia nigra. These data provide evidence of neuroprotection by aminoindan and rasagiline via their ability to enhance BDNF lev 15 January 2016
  • Molecular Neurodegeneration Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseConclusions: Simultaneous inhibition of MAO-B and oxidative stress induced pathological dopamine release by the novel propargylamines is protective in animal models and seems a plausible strategy to combat Parkinson's disease. 13 January 2016
  • Nature Communications Impairment of PARK14-dependent Ca2+ signalling is a novel determinant of Parkinson's diseaseHere authors demonstrate that genetic or molecular impairment of PLA2g6-dependent Ca2+ signalling is a trigger for autophagic dysfunction, progressive loss of dopaminergic (DA) neurons in substantia nigra pars compacta and age-dependent L-DOPA-sensitive motor dysfunction. 12 January 2016
  • Parkinson's Disease Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's DiseaseThe role of environmental exposure, as well as the contribution of single genetic risk factors, is still controversial. In most of PD cases, disease onset is probably triggered by a complex interplay of many genetic and nongenetic factors, each of which conveys a minor increase in the risk of disease. This review summarizes the current knowledge on causal mutation for PD, susceptibility factors increasing disease risk, and the genetic factors that modify the impact of environmental exposure. 11 January 2016
  • Neural Regeneration Research Verbascoside promotes the regeneration of tyrosine hydroxylase-immunoreactive neurons in the substantia nigraAfter 6 weeks of verbascoside treatment, rat rotational behavior was alleviated; tyrosine hydroxylase mRNA and protein expression and the number of tyrosine hydroxylase-immunoreactive neurons in the rat right substantia nigra were significantly higher than the Parkinson's model group. These findings suggest that the mechanism by which verbascoside treats Parkinson's disease is related to the regeneration of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra. 01 January 2016
  • Neurochemistry International Volume 61 Issue 7 Neuroprotective Effects of Caffeine in MPTP Model of Parkinson's Disease: A 13C NMR StudyIn this study, authors evaluated the neuroprotective effect of caffeine in the MPTP model of PD by monitoring the region specific cerebral energy metabolism. Adult C57BL6 mice were treated with caffeine (30 mg/kg, i.p.) 30 min prior to MPTP (25 mg/kg, i.p.) administration for 8 days. 01 January 2016
  • Parkinsonism & Related Disorders Supplement Genetic Susceptibility Variants in ParkinsonismWithin this review authors will highlight the genetic loci that are associated with disease and discuss the implications and importance for a better understanding of the genes involved and thus the underlying pathophysiology of these disorders. 01 January 2016
  • Journal of Neurochemistry Chronic and progressive Parkinson's disease MPTP model in adult and aged miceHere, authors undertook a histological, neurochemical and behavioural analysis of a new chronic parkinsonian mouse model generated by the subcutaneous administration of low doses of MPTP (20 mg/kg, 3 times per week) for 3 months, using both young adult and aged mice. The MPTP-induced nigrostriatal neurodegeneration was progressive and was accompanied by a decrease in striatal dopamine levels and motor impairment. 01 January 2016
  • Parkinsonism & Related Disorders Volume 22 Supplement 1 Autosomal dominant Parkinson's disease caused by SNCA duplicationsNeuronal loss in the hippocampal cornu ammonis 2/3 regions were seen in about half of the autopsied SNCA duplication cases. Similar pathology was also observed in SNCA missense mutation and triplication carriers. 01 January 2016
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]